deltatrials
Completed NA INTERVENTIONAL 2-arm NCT02255253

Telmisartan and Hydrochlorothiazide Antihypertensive Treatment Study in High Sodium Intake Population

Efficacy of Telmisartan 40mg and Hydrochlorothiazide 25mg Monotherapy in High Sodium Intake Patients With Mild to Moderate Hypertension: a Multicenter Randomized Double-blinded Parallel Controlled Trial

Sponsor: Peking University People's Hospital

Conditions Hypertension
Updated 5 times since 2017 Last updated: Mar 9, 2015 Started: Oct 31, 2014 Primary completion: Feb 28, 2015 Completion: Mar 31, 2015
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Hypertension and is currently completed. Peking University People's Hospital leads this study, which shows 5 recorded versions since 2014 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

5 versions recorded
  1. Sep 2024 — Present [monthly]

    Completed NA

  2. Jul 2024 — Sep 2024 [monthly]

    Completed NA

  3. Jan 2021 — Jul 2024 [monthly]

    Completed NA

  4. Jun 2018 — Jan 2021 [monthly]

    Completed NA

  5. Jan 2017 — Jun 2018 [monthly]

    Completed NA

    First recorded

Oct 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Peking University People's Hospital
  • The George Institute for Global Health, China
Data source: The George Institute for Global Health, China

For direct contact, visit the study record on ClinicalTrials.gov .